Cell Signaling Technology

Product Pathways - Neuroscience

ApoE4 (4E4) Mouse mAb #8941

Applications Reactivity Sensitivity MW (kDa) Isotype
W H Endogenous 35 Mouse IgG1

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

ApoE4 (4E4) Mouse mAb recognizes endogenous levels of total ApoE4 protein. This antibody does not cross-react with ApoE2 or ApoE3.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg130 of human ApoE4 protein.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, transfected with a construct expressing full-length human ApoE2 (hApoE2; +), ApoE3 (hApoE3; +), or ApoE4 (hApoE4; +), using ApoE4 (4E4) Mouse mAb (upper) or a pan ApoE antibody (lower).

Western Blotting

Western Blotting

Western blot analysis of human serum using ApoE4 (4E4) Mouse mAb.

Background

Apolipoproteins are plasma lipoproteins that function as transporters of lipids and cholesterol in the circulatory system. Chylomicrons are a fundamental class of apolipoproteins containing very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) (1,2).

Human ApoE has three isoforms: ApoE2, ApoE3, and ApoE4. These three isoforms differ in the combination of cysteine and arginine residues located at positions 130 and 176. The ApoE4 isoform contains arginine at both locations. Research studies have linked ApoE4 function to neuronal plasticity, synaptogenesis, and neurodegenerative diseases (3). ApoE4 is produced in the liver and brain, although it is widely expressed in other tissues, such as the lung, spleen, and ovary. Investigators have established the ApoE4 allele as a genetic risk factor for Alzheimer’s disease (AD), accounting for 50-60% of the genetic variation in the disease (4). Research studies indicate that patients expressing ApoE4 have a reduced capacity for synaptic plasticity, an earlier age of onset of AD, and an increase in amyloid-beta (Aβ) deposition. The increase in Aβ suggests a role for ApoE4 in the impairment of amyloid clearance (5).

  1. Kwiterovich, P.O. (2000) Am J Cardiol 86, 5L-10L.
  2. Hussain, M.M. (2000) Atherosclerosis 148, 1-15.
  3. Raber, J. et al. Neurobiol Aging 25, 641-50.
  4. Corder, E.H. et al. (1993) Science 261, 921-3.
  5. Holtzman, D.M. et al. (2000) Proc Natl Acad Sci U S A 97, 2892-7.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products